Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
1999-11-12
2002-07-30
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S183000, C435S190000, C435S200000, C435S206000, C435S210000
Reexamination Certificate
active
06426208
ABSTRACT:
FIELD OF THE INVENTION
The present invention is in the field of molecular biology, enzymology, biochemistry and clinical medicine. In particular, the present invention provides a recombinant &agr;-L-iduronidase, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including &agr;-L-iduronidase deficiency and mucopolysaccharidosis I (MPS I).
BACKGROUND OF THE INVENTION
Carbohydrates play a number of important roles in the functioning of living organisms. In addition to their metabolic roles, carbohydrates are structural components of the human body covalently attached to numerous other entities such as proteins and lipids (called glycoconjugates). For example, human connective tissues and cell membranes comprise proteins, carbohydrates and a proteoglycan matrix. The carbohydrate portion of this proteoglycan matrix provides important properties to the body's structure.
A genetic deficiency of the carbohydrate-cleaving, lysosomal enzyme &agr;-L-iduronidase causes a lysosomal storage disorder known as mucopolysaccharidosis I (MPS I) (Neufeld, E. F., and Muenzer, J. (1989). The mucopolysaccharidoses in “The Metabolic Basis of Inherited Disease” (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., Eds.), pp. 1565-1587, McGraw-Hill, New York). In a severe form, MPS I is commonly known as Hurler syndrome and is associated with multiple problems such as mental retardation, clouding of the cornea, coarsened facial features, cardiac disease, respiratory disease, liver and spleen enlargement, hernias, and joint stiffness. Patients suffering, from Hurler syndrome usually die before age 10. In an intermediate form known as Hurler-Scheie syndrome, mental function is generally not severely affected, but physical problems may lead to death by the teens or twenties. Scheie syndrome is the mildest form of MPS I. It is compatible with a normal life span, but joint stiffness, corneal clouding and heart valve disease cause significant problems.
The frequency of MPS I is estimated to be 1:100,000 according to a British Columbia survey of all newborns (Lowry et al.,
Human Genetics
85:389-390 (1990)) and 1:70,000 according to an Irish study (Nelson,
Human Genetics
101:355-358 (1990)). There appears to be no ethnic predilection for this disease. It is likely that worldwide the disease is underdiagnosed either because the patient dies of a complication before the diagnosis is made or because the milder forms of the syndrome may be mistaken for arthritis or missed entirely. Effective newborn screening for MPS I would likely find some previously undetected patients.
Except for bone marrow transplantation, there are no significant therapies available for MPS I. Bone marrow transplants can be effective in treating some of the symptoms of the disorder but have high morbidity and mortality in MPS I and often are not available to patients because of a lack of suitable donors. An alternative therapy available to all affected patients would provide an important breakthrough in treating an d managing this disease.
Enzyme replacement therapy has long been considered a potential therapy for MPS I following the discovery that &agr;-L-iduronidase can correct the enzymatic defect in Hurler cells in culture. In this corrective process, the enzyme containing a mannose-6-phosphate residue is taken up into cells through receptor-mediated endocytosis and transported to the lysosomes where it clears the stored substrates, heparan sulfate and dermatan sulfate. Application of this therapy to humans has previously not been possible due to inadequate sources of &agr;-L-iduronidase in tissues. The enzyme replacement concept was first effectively applied to Gaucher patients in a modified placental glucocerebrosidase. The delivery and effective uptake of glucocerebrosidase in Gaucher patients demonstrated that an enzyme could be taken up in vivo in sufficient quantities to provide effective therapy.
For &agr;-L-iduronidase enzyme therapy in MPS I, a recombinant source of enzyme has been needed in order to obtain therapeutically sufficient supplies of the enzyme. The mammalian enzyme was cloned in 1990 (Stoltzfus et al.,
J. Biol. Chem.
267:6570-6575 (1992), and the human enzyme was cloned in 1991 (Moskowitz et al.,
FASEB J
6:A77 (1992)).
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3891757 (1975-06-01), Higuchi
patent: 5270051 (1993-12-01), Harris
patent: 1001949 (1965-08-01), None
patent: WO 93/10244 (1993-05-01), None
patent: WO 99/51724 (1999-10-01), None
patent: WO 99/58691 (1999-11-01), None
Clements, et al., “Human alpha-L-iduronidase 1. Purification, monoclonal and antibody production, native and subunit molecular mass”,European Journal of Biochemistry, 152(1):43-49 (1994).
Kakkis, et al., “Enzyme-replacement therapy in mucopolysaccharidosis I.”,New England Journal of Medicine, 344(3):182-188 (2001).
Anson, D. S., et al., “Correction of Human Mucopolysaccharidosis Type-VI Fibroblasts with Recombinant N-Acetylgalactosamine-4-Suplphatase,”Biochem J.—284:789-794 (1992).
Barton, R. W., et al., “The Hurler Corrective Factor,”J. Biol. Chem.—246(24):7773-7779 (1971).
Bielicki, J., et al., “Recombinant Human Iduronate-2-Sulphatase: Correction of Mucopolysaccharidosis-Type II Fibbroblasts and Characterization of the Purified Enzyme,”Biochem. J.—289:241-246 (1993).
Friedman, T., “Progress Toward Human Gene Therapy,”Science—244:1275-1281 (1989).
Hoogerbrugge, P.M., et al., “Allogeneic Bone Marrow Transplantation for Lysosomal Storage Diseases,”Lancet—345:1398 (1995).
Ioannou, Y.A., et al., “Overexpression of Human &agr;-Galactosidase A Results in Its Intacellular Aggregation, Crystallization in Lysosomes, and Selective Secretion,”J. Cell Biol.—119(5):1137-1150 (1992).
Kakkis, E.D., et al., “Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis1,”—58(2):156-157 (1996).
Kakkis, E., et al., “Strong Transcriptional Activation of Translocated C-Myc Genes Occurs Without a Strong Nearby Enhancer or Promoter,”Nucleic Acids Res.—16(1):77-96 (1988).
Ledley, F.D., “Clinical Application of Somatic Gene Therapy in Inborn Errors of Metabolism,”J. Inherit. Metab. Dis.—13:597-616 (1990).
Lowry, R.B., et al. “An Update on the Frequency of Mucopolysaccharide Syndromes in British Columbia,”Human Genetics—85:389-390 (1990).
Myerowitz, R., et al., “Maturation of &agr;-L-Iduronidase in Cultured Human Fibroblasts,”J. Biol. Chem.—256(6):3044-3048 (1981).
Moskowitz, S.M., et al., “Cloning and Expression of cDNA Encoding the Human Lysosomal Enzyme, &agr;-L-Iduronidase,”FASEB J.—6:A77 (1992).
Nelson, J., “Incidence of the Mucopolysaccharidoses in Northern Ireland,”Human Genetics—101:355-358 (1997).
Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. Eds.The Metabolic Basis of Inherited Diseasepp. 1565-1587, McGraw Hill, New York (1989).
Shull, R.M., et al., “Enzyme Replacement in a Canine Model of Hurler Syndrome,”Proc. Natl. Acad. Sci., USA—91:12937-12941 (1994).
Stoltzfus, L.J., et al., “Cloning and Characterization of cDNA Encoding Canine &agr;-L-Iduronidase,”J. Biol. Chem.—267(10):6570-6575 (1992).
Taylor, J., et al., “&agr;-L-Iduronidase in Normal and Mucopolysaccharidosis—Type-1 Human Skin Fibroblasts,”Biochem J.—274:263-268 (1991).
Tolstoshev, P., et al., “Gene Expression Using Retroviral Vectors,”Current Opinions Biotech.—1:55-61 (1990).
Tucker, P.W., et al., “Mouse IgA Heavy Chain Gene Sequence: Implications for Evolution of Immunoglobulin Hinge Exons,”Proc. Natl. Acad. Sci. USA—78(12):7684-7688 (1981).
Unger, E.G., et al., “Recombinant &agr;-L-Iduronidase: Characterization of the Purified Enzyme and Correction of Mucopolysaccharidosis Type I Fibroblasts,”Biochem. J.—304:43-49 (1994).
Kakkis Emil D.
Tanamachi Becky
Achutamurthy Ponnathapu
Chiang Robin C.
Halluin Albert P.
Harbor-UCLA Research and Education Institute
Howrey Simon Arnold & White , LLP
LandOfFree
Recombinant &agr;-L-iduronidase, methods for producing and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant &agr;-L-iduronidase, methods for producing and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant &agr;-L-iduronidase, methods for producing and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2880894